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Abstract 
Patients with recurrent or metastatic cancer commonly suffer from debilitating toxicity 
associated with conventional treatment modalities, as well as disease-related symptoms, often 
with a concomitant negative impact on health-related quality of life (HRQoL). Patient-reported 
outcomes (PROs) provide important insights into the patient experience in clinical trials. 
Nivolumab is a programmed death-1 receptor inhibitor that extends survival in patients with 
recurrent or metastatic disease in multiple tumor types. In this review, we summarize published 
PRO analyses from eight phase II−IV clinical trials with nivolumab for the treatment of 
melanoma, non-small cell lung cancer, renal cell carcinoma (RCC), and squamous cell 
carcinoma of the head and neck (SCCHN). Symptom burden, physical functioning, and HRQoL 
were measured using generic, cancer-specific, and tumor type–specific validated PRO 
instruments. Nivolumab showed sustained stabilization across all tumor types and, in some 
cases, clinically meaningful improvement in HRQoL, whereas standard of care therapies often 
led to deteriorations. Exploratory analyses found a positive correlation between baseline HRQoL 
scores and overall survival in RCC, and between baseline HRQoL scores and healthcare 
resource utilization in SCCHN, suggesting that patient-reported symptoms at treatment initiation 
may have clinical value. In the era of value-based oncology care, stakeholders are increasingly 
interested in PRO findings to guide clinical, regulatory, and reimbursement decisions. However, 
missing data remain a significant challenge in PRO analyses, including in nivolumab trials. 
Future clinical trials in immuno-oncology should incorporate PRO data collection, including 
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Highlights 
 PROs reported from eight nivolumab trials in four types of advanced cancer  
 PROs were assessed using generic, cancer-specific, and tumor type–specific measures  
 Nivolumab generally sustained/improved HRQoL, and improved functioning 
 Nivolumab benefits versus chemotherapy or targeted therapy seen across tumor types  
 PROs may be a differentiating factor between PD-1 inhibitors and other treatments 
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Introduction 
Evaluation of novel therapies in oncology should include not only clinical outcomes, but 
also patient-reported outcomes (PROs) that reflect patients’ perceptions of their physical, 
mental, and social health status, without interpretation by a clinician or another intermediary (1). 
PROs assess health-related quality of life (HRQoL) or components that contribute to HRQoL 
such as disease-related or treatment-related symptoms and typical daily functioning, 
incorporating the patient’s voice to provide a holistic understanding of patient experiences 
beyond conventional clinical endpoints. PRO findings can help patients, oncologists, payers, 
and regulators evaluate the tolerability and benefits of therapies comprehensively, and provide 
additional differentiation between treatment options. While patients with cancer rank survival as 
their highest priority, they also value HRQoL during and after treatment (2). Although advances 
have been made in clinical outcomes, well-being during initial treatment and throughout cancer 
survivorship remains a critical unmet need for patients (3).  
The majority of systemic treatments for advanced cancers have remained fundamentally 
palliative. Furthermore, conventional treatments cause debilitating toxicity that negatively affects 
HRQoL in most patients, including those without clinical benefits. HRQoL assessment is 
especially important for immunotherapies that may require longer treatment durations and, for 
some patients, may enable long-term survival beyond historic benchmarks. Patients may also 
value the “hope” of improved survival potentially provided by novel therapies (4). 
Immune checkpoint blockade is an effective therapeutic strategy that harnesses the 
immune system to generate an antitumor response (5). Nivolumab and ipilimumab are 
antibodies that bind to the immune-modulating programmed death-1 (PD-1) and cytotoxic T 
lymphocyte antigen-4 (CTLA-4) receptors, respectively, blocking ligand interaction and 
downstream signaling pathways. This disrupts the negative regulation of T-cell function, 
potentially resulting in an antitumor effect. Nivolumab, alone or in combination with ipilimumab, 
prolongs survival and is currently approved in a number of cancers (6).  
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Immune checkpoint inhibitors have safety profiles distinct from those of cytotoxic and 
targeted therapies, which may translate into HRQoL benefits. PD-1 inhibitors typically cause 
fewer and less severe treatment-related adverse events (TRAEs) compared with conventional 
chemotherapies, although immune-related adverse events (AEs) can occur, requiring 
monitoring and specialized management to prevent serious complications (7). In the initial 
nivolumab trials, grade 3-4 immune-related AEs of colitis were reported in 1%−17% of patients, 
followed by diarrhea (1%−11%), rash (<1%−5%) and hypophysitis (<1%−3%). TRAEs tended to 
be low-grade; those most commonly reported were fatigue, nausea, rash, diarrhea, pruritis, and 
decreased appetite. Grade 3 or 4 anemia or neutropenia, which are common toxicities 
associated with chemotherapy, were reported in <1%−2% of patients treated with nivolumab (8-
15). 
PROs have been included as secondary or exploratory endpoints in nivolumab clinical 
trials across multiple tumor types, providing a unique opportunity to evaluate the impact of 
nivolumab on HRQoL in patients with highly symptomatic, advanced cancers.  
 
PRO instruments and assessments in the nivolumab trials 
PROs are collected by administering questionnaires that are scored and quantitatively 
analyzed to evaluate patients’ symptoms, functioning, or general well-being. Numerous PRO 
instruments have been designed using robust methodologies, focusing on a disease, condition, 
or overall health status, and psychometrically validated in the target patient population to ensure 
relevance, consistency, sensitivity, and correlation with other measures (16, 17). The PROs 
used in nivolumab trials reviewed here included a generic HRQoL measure, the EuroQoL five 
dimensions (EQ-5D) 3-level version (18-20), and at least one cancer-specific measure (Table 
1). The cancer-specific measures were the general cancer European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) (21), as well 
as the tumor type–specific Lung Cancer Symptom Scale (LCSS) for non-small cell lung cancer 
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(NSCLC) (22, 23), the Functional Assessment of Cancer Therapy-Kidney Symptom Index-
Disease Related Symptoms (FKSI-DRS) for renal cell carcinoma (RCC) (24), and the EORTC 
35-Question Head and Neck Cancer-Specific Module (EORTC QLQ-H&N35) for squamous cell 
carcinoma of the head and neck (SCCHN) (25, 26).  
In the nivolumab trials described, PROs were collected prior to treatment initiation and at 
multiple time points during treatment and follow-up, enabling assessment of changes over time. 
This review focuses on data collected during treatment, with exceptions noted in the text. During 
study visits, patients completed questionnaires prior to physician contact, treatment dosing, or 
any procedures. The timing of assessments differed by trial; therefore, comparisons across 
trials at specific time points were not always possible, although general trends were assessed. 
Completion rates were calculated for each PRO measure based on the proportion of patients 
alive in the study at that time. In some trials, adjusted completion rates representing the 
proportion of patients with a baseline assessment and at least one post-baseline assessment 
were reported.  
PRO data were assessed using descriptive statistics within each treatment arm, 
comparing scores during treatment to baseline scores and between treatment arms at specific 
time points. Longitudinal changes from baseline within and between arms were assessed with 
mixed-effects models for repeated measures (MMRM). Time to deterioration or improvement in 
HRQoL, defined based on clinically meaningful change in score, was determined using Kaplan-
Meier methodology. A clinically meaningful change in score represents a treatment benefit or 
harm perceptible by the patient and significant enough to warrant a modification to the patient’s 
clinical management. Changes in scores are also often interpreted relative to the minimally 
important difference (MID), which is the smallest difference in score that patients perceive as 
beneficial or detrimental, and is established by extensive anchor-based and/or distribution-
based quantitative analyses (18, 27-29). Clinical relevance and the MID vary by patient 
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population and clinical context of treatment, such that a PRO instrument can have more than 
one MID or a range of MID estimates (Table 1). 
All studies included in this review were conducted in accordance with the ethical 
principles defined by Declaration of Helsinki. All patients provided informed written consent prior 
to study enrollment. 
 
Results of PRO assessments in nivolumab trials 
Nearly all patients (98%−100%) included in the initial nivolumab trials were categorized 
as high-functioning at baseline by either Eastern Cooperative Oncology Group performance 
status score (0−1) or Karnofsky performance score (≥70), across tumor types (8-15). This 
review presents published PRO data from eight nivolumab studies, predominantly randomized 
phase III trials, in four advanced solid cancers: melanoma, NSCLC, RCC, and SCCHN (Table 
2). Key PRO data are summarized in Table 3 and discussed by tumor type below.  
 
Melanoma 
CheckMate 066 was a randomized, double-blind, phase III trial that compared nivolumab 
with dacarbazine in patients with treatment-naive metastatic melanoma with wild-type BRAF 
(10). Nivolumab was associated with a significant survival benefit and lower risk of high-grade 
toxicity compared with dacarbazine. PROs were included in the trial as secondary (EORTC 
QLQ-C30) and exploratory (EQ-5D) endpoints (30). 
Questionnaire completion rates for both questionnaires at baseline were 70% for the 
nivolumab arm and 65% for the dacarbazine arm, and remained similar to baseline throughout 
treatment when adjusted for patients alive. A high attrition rate in the dacarbazine arm, likely 
because of disease progression or death, resulted in small sample sizes after week 13 (n ≤ 41), 
limiting comparative HRQoL analysis between arms to early time points.  
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Patients receiving nivolumab maintained HRQoL levels at or above baseline over time, 
with clinically meaningful improvements in EQ-5D utility index (UI) and visual analog scale 
(VAS) scores at multiple time points. Patients receiving dacarbazine had no significant or 
clinically meaningful changes in EQ-5D UI and VAS scores from baseline. Nivolumab 
significantly delayed time to deterioration in EQ-5D UI relative to dacarbazine; however, for the 
cancer-specific EORTC QLQ-C30 scales, no significant differences within or between arms 
occurred at any time point. 
A pattern mixture model (PMM) sensitivity analysis of missing data found no significant 
interaction between treatment and dropout except for the EQ-5D VAS longitudinal analysis, 
suggesting that missing data may have muted the magnitude of the improvement in EQ-5D VAS 
scores among patients treated with nivolumab. 
CheckMate 067, a randomized, double-blind, phase III trial in treatment-naive patients 
with metastatic melanoma, compared nivolumab plus ipilimumab with each agent alone (11, 
13). Single-agent nivolumab and nivolumab plus ipilimumab showed greater efficacy than 
single-agent ipilimumab. Combination therapy was associated with higher rates of grade 3–4 
TRAEs versus each single-agent therapy, potentially diminishing HRQoL. PROs were included 
in this trial as secondary (EORTC QLQ-C30) and exploratory (EQ-5D) endpoints (31). 
Adjusted questionnaire completion rates for the EORTC QLQ-C30 and EQ-5D at 
baseline were between 82% and 87% in each of the three treatment arms. Completion rates 
remained ≥50% in all arms for both questionnaires through week 67. 
HRQoL was maintained relative to baseline in the single-agent nivolumab and nivolumab 
plus ipilimumab arms, with no clinically meaningful difference versus single-agent ipilimumab. 
Subgroup analyses were conducted among patients with mutated BRAF, wild-type BRAF, 
complete response (CR) or partial response (PR), grade 3–4 AEs, and treatment discontinuation 
for any reason or due to AEs. There were no significant deteriorations in the single-agent 
nivolumab or nivolumab plus ipilimumab arms in any of these subgroups, except for EORTC 
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QLQ-C30 Global Health score in the nivolumab plus ipilimumab arm at week 17, and for EQ-5D 
VAS score at 4 weeks (follow-up visit 1) and 16 weeks (follow-up visit 2) after the last dose of 
treatment among patients receiving nivolumab plus ipilimumab who discontinued due to AEs. In 
the wild-type BRAF subgroup, those treated with nivolumab had a clinically meaningful 
improvement at weeks 31–37. 
Nivolumab plus ipilimumab also demonstrated greater clinical activity and increased 
frequency of grade 3−4 TRAEs versus single-agent ipilimumab in CheckMate 069, a 
randomized, double-blind, phase II trial in treatment-naive patients with advanced melanoma 
(9). PROs were included as secondary (EORTC QLQ-C30) and exploratory (EQ-5D) endpoints 
(32). 
Questionnaire completion rates at baseline were 65% (EORTC QLQ-C30) and 64% 
(EQ-5D) for the nivolumab plus ipilimumab arm, and 79% (EORTC QLQ-C30) and 77% (EQ-
5D) for the ipilimumab arm, and remained stable throughout treatment except for a reduction at 
week 13 with nivolumab plus ipilimumab (48%). PRO data were analyzed between baseline and 
week 25 of treatment, beyond which small patient numbers precluded analysis.  
Throughout the analysis period, patients treated with nivolumab plus ipilimumab and 
single-agent ipilimumab maintained HRQoL at baseline levels. There were no clinically 
meaningful changes in either treatment arm for any of the EORTC QLQ-C30 scales nor the EQ-
5D outcomes. Cox proportional hazards regression analyses revealed no significant differences 
between treatment arms in the hazards for time to improvement or deterioration (as defined by 
scale MID or clinically important difference, applied at the individual patient level). 
A PMM analysis assessing the impact of dropout patterns on longitudinal changes 
showed that, in most cases, early (last assessment weeks 7 or 13) or late (last assessment 
week 19 or later) dropout did not impact MMRM results. However, for the EORTC QLQ-C30 
physical functioning scale, early dropout in both treatment arms was associated with 
deterioration. 
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Non-small cell lung cancer 
In the randomized, open-label, phase III CheckMate 017 trial, nivolumab significantly 
prolonged overall survival (OS) compared with docetaxel in previously treated patients with 
locally advanced or metastatic squamous cell NSCLC (14). This trial included an analysis of the 
proportion of patients with disease-related symptom improvement by week 12 using the LCSS 
as a secondary endpoint (33).  
Adjusted LCSS completion rates were 69% (nivolumab) and 63% (docetaxel). At week 
12, a similar proportion of patients in the nivolumab (20%) and docetaxel (22%) arms had 
clinically meaningful symptom improvement, as measured by the LCSS Average Symptom 
Burden Index (ASBI). However, at later time points, patients continuing on nivolumab showed 
reduced symptom burden over time, whereas those receiving docetaxel had stabilized or 
worsened symptoms.  
LCSS ASBI score changes from baseline in the nivolumab arm indicated clinically 
meaningful improvements between weeks 42 and 84, whereas no significant or clinically 
meaningful changes were observed in the docetaxel arm. A longitudinal analysis showed that 
ASBI score (p = 0.028) and its fatigue component (p <0.001) were significantly better in patients 
treated with nivolumab than in those who received docetaxel; there was an improvement in 
cough in the nivolumab arm that was statistically significant (p < 0.001) and clinically 
meaningful. Analyses of time to deterioration based on MID revealed significantly slower 
deterioration in anorexia (p = 0.009), symptom distress (p = 0.026), interference with activity 
level (p = 0.004), and global HRQoL (p = 0.007) among patients who received nivolumab versus 
those who received docetaxel.  
Analyses of the LCSS 3-Item Index revealed statistically significant improvements 
compared with baseline in the nivolumab arm at weeks 24, 42–54, and 66, but clinically 
meaningful deterioration in the docetaxel arm at weeks 30 and 36. Statistically significant 
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improvements were observed for patients treated with nivolumab versus docetaxel at weeks 
30–54. Longitudinal analysis showed that, based on the MID, nivolumab significantly slowed 
time to deterioration in the LCSS 3-Item Index compared with docetaxel (p = 0.005). 
Similar trends were observed with the EQ-5D. Adjusted EQ-5D completion rates were 
higher for nivolumab (72%) compared with docetaxel (64%). At week 12, completion rates were 
similar for both treatment arms (nivolumab, 70%; docetaxel, 71%). By week 42, scores in EQ-
5D UI among patients receiving nivolumab were more favorable than mean scores reported for 
a general US population (34), whereas throughout treatment, scores for patients receiving 
docetaxel were similar to the norm for a lung cancer population (18) (Fig. 1). For the EQ-5D 
VAS, patients who received nivolumab had clinically meaningful improvements from baseline 
and achieved mean scores exceeding that of the general population at weeks 48 and 60, 
whereas those receiving docetaxel maintained a level of health consistent with that of patients 
with lung cancer, with no clinically meaningful changes. Nivolumab significantly delayed time to 
deterioration versus docetaxel for both the EQ-5D UI (p = 0.006) and VAS (p = 0.008), with the 
curves beginning to separate before 2 months. 
Nivolumab has also demonstrated significantly longer OS and a favorable safety profile 
compared with docetaxel in advanced, previously treated non-squamous NSCLC in CheckMate 
057, a randomized, open-label, phase III trial (8). Improvement in disease-related symptoms by 
week 12 was assessed as a secondary endpoint using the LCSS (35). Overall health status, 
assessed using the EQ-5D, was an exploratory objective (36). Questionnaire completion rates 
were generally similar between the nivolumab and docetaxel arms at baseline (EQ-5D: 84% vs. 
80%; LCSS: 82% vs. 77%) and at week 12 (EQ-5D: 77% vs. 80%; LCSS: 77% vs. 76%).  
The rate of disease-related symptom improvement by week 12, defined as a ≥10-point 
decrease from baseline in LCSS ASBI score at any time from randomization to week 12, was 
similar in both arms: 18% with nivolumab and 20% with docetaxel. Nivolumab was associated 
with a brief worsening in ASBI score at week 4 (p = 0.033), followed by significant 
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improvements from weeks 16 to 54, with clinically meaningful improvements in cough from 
weeks 36 to 48. Docetaxel was associated with worsening in ASBI score relative to baseline at 
week 9 (p = 0.018), after which ASBI scores indicated stable symptoms. Numerical between-
arm differences in ASBI score changes from baseline were observed in favor of nivolumab from 
week 12 (first common PRO assessment time point) throughout treatment. An MMRM 
longitudinal analysis showed improvements from baseline in the nivolumab arm for fatigue (p = 
0.032) and cough (p = 0.046), and deterioration from baseline in the docetaxel arm for ASBI (p 
= 0.001), fatigue (p < 0.001), and dyspnea (p < 0.001); however, changes were not clinically 
meaningful. Time to deterioration in ASBI score (p = 0.002) and most of its individual 
components was delayed with nivolumab versus docetaxel, with Kaplan-Meier curves 
separating at approximately 2 months. 
At common assessment time points with >10 patients (to week 48), between-arm 
differences in the change from baseline in LCSS 3-Item Index score were significant at weeks 
24 and 30, favoring nivolumab over docetaxel. There was a clinically meaningful improvement in 
HRQoL at week 48 in the nivolumab arm. Time to deterioration in the LCSS 3-Item Index (p < 
0.001) and its components was slower with nivolumab versus docetaxel, with Kaplan-Meier 
curves also separating at approximately 2 months. 
Apart from a worsening at week 4 (p = 0.008) in the nivolumab arm that was not clinically 
meaningful, neither arm exhibited statistically significant changes in EQ-5D UI scores from 
baseline. Patients treated with nivolumab exhibited clinically meaningful improvements from 
baseline in EQ-5D VAS scores at weeks 24 and 36; there were no significant differences 
between arms for any on-treatment assessments.  
Longitudinal and time-to-deterioration analyses showed no differences between 
treatment arms for the EQ-5D UI. However, an MMRM analysis for the EQ-5D VAS showed a 
significant improvement from baseline with nivolumab (p = 0.021) and no changes with 
docetaxel; between-arm differences favored nivolumab (p = 0.002). Time to deterioration based 
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on the EQ-5D VAS was delayed with nivolumab versus docetaxel (p = 0.032), with Kaplan-
Meier curves separating at approximately 4 months. 
In a community-based phase IIIb/IV trial (CheckMate 153) of nivolumab in patients with 
previously treated stage IIIB/IV squamous or non-squamous NSCLC, PROs were assessed as 
secondary endpoints using the LCSS and EQ-5D instruments (37). Based on the available data 
from this ongoing trial, LCSS ASBI and 3-Item Index scores remained stable from baseline to 
week 6, then improved steadily though week 30. Subgroup analyses showed that patients with 
PR (no patients had a CR) had improvements in LCSS ASBI scores from baseline to week 6. 
After week 6, all response-evaluable groups (PR, stable disease, and progressive disease) 
trended toward improvement. For the LCSS 3-Item Index, all three response groups had 
improvements from weeks 6 to 18. There were no HRQoL differences between programmed 
death ligand 1 (PD-L1) non-expressers (<1%), expressers (≥1%), and indeterminate 
expressers, based on LCSS ASBI or 3-Item Index scores.  
Both EQ-5D UI and VAS scores improved over time with nivolumab treatment, with 
significant improvements from weeks 12 to 24. EQ-5D VAS scores showed clinically meaningful 
improvements from weeks 18 to 30, approaching the United States population norm by week 
30. Subgroup analyses showed an improvement trend between baseline and week 18 among 
patients with PR and stable disease, with a clinically meaningful improvement at week 18 for the 
PR group. There were no differences between PD-L1 non-expressers, expressers, and 
indeterminate expressers for the EQ-5D VAS, while current/former smokers with squamous 
histology and non-smokers with non-squamous histology had clinically meaningful 
improvements from baseline at week 18. Patients regardless of age, as well as those with an 
Eastern Cooperative Oncology Group performance status of 0–1, showed improvements in 
mean EQ-5D VAS score. Patients with a performance status of 2 had lower EQ-5D VAS scores 
at baseline but showed improvements from week 6 onwards (38).  
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Renal cell carcinoma 
In CheckMate 025, a randomized, open-label, phase III trial in previously treated patients 
with advanced RCC, nivolumab improved OS versus everolimus, an mTOR inhibitor (12). PROs 
were assessed as exploratory endpoints using the FKSI-DRS questionnaire and EQ-5D (39). 
Adjusted baseline completion rates were 89% in the nivolumab arm and 86–87% in the 
everolimus arm. 
Patients treated with nivolumab had improved FKSI-DRS scores relative to baseline 
from weeks 20–104, whereas in patients treated with everolimus, scores deteriorated relative to 
baseline between weeks 4–32 and 60–64 (Fig. 2), with significant differences between 
treatment arms. Scores were improved with nivolumab versus everolimus for all nine individual 
FKSI-DRS items. Longitudinal MMRM showed that patients receiving everolimus experienced 
clinically meaningful deterioration from baseline through week 84, whereas scores remained 
stable during the same period for patients receiving nivolumab. A higher proportion of patients 
treated with nivolumab (55%) had clinically meaningful improvements versus patients treated 
with everolimus (37%) (p < 0.0001). Using a more stringent scoring threshold (MID of ≥3 points), 
41% of patients treated with nivolumab had clinically meaningful improvements versus 28% of 
patients treated with everolimus (p = 0.0002). Median time to improvement was shorter in 
patients treated with nivolumab versus everolimus. 
EQ-5D UI and VAS scores improved from baseline to week 104 with nivolumab, 
whereas deterioration occurred with everolimus. With the EQ-5D UI, there was no significant 
difference between the treatment arms in the proportion of patients who had clinically 
meaningful improvement, or in the hazard ratios for time to improvement. However, more 
patients had clinically meaningful improvements in EQ-5D VAS scores with nivolumab (53%) 
versus everolimus (39%) (p = 0.0001). Time to improvement, as assessed with the EQ-5D VAS, 
was 6.5 months with nivolumab and 23.1 months with everolimus (p = 0.070). 
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An exploratory analysis suggested that OS was positively correlated with PROs based 
on the FKSI-DRS, EQ-5D UI, and EQ-5D VAS (39, 40). Median OS was longest in patients with 
high baseline scores (above the median) and improvements from baseline, and shortest in 
patients with low baseline scores (below the median), suggesting that baseline PRO scores 
could to be prognostic indicators of clinical outcomes. 
 
Squamous cell carcinoma of the head and neck 
CheckMate 141 was a phase III randomized, open-label trial of nivolumab versus 
investigator’s choice (IC) of single-agent chemotherapy (cetuximab, docetaxel, or methotrexate) 
in recurrent or metastatic platinum-refractory SCCHN (15). Treatment with nivolumab resulted in 
longer OS and was associated with fewer grade 3–4 AEs compared with IC. HRQoL was 
assessed as an exploratory endpoint using EORTC QLQ-C30, EORTC QLQ-H&N35, and EQ-
5D (41). 
Questionnaire completion rates were 80% for nivolumab (all questionnaires) and 74–
75% for IC at baseline, and precipitously decreased over time. Owing to small sample sizes (n < 
10) in the IC arm, analyses comparing treatment arms were not conducted beyond week 15. An 
analysis of missing data showed that, generally, patients who had only completed a baseline 
assessment had lower functioning and higher symptom burden than patients who also 
completed questionnaires during treatment. Before dropout, both EORTC questionnaire scores 
remained stable in the nivolumab arm but declined in the IC arm, suggesting that estimates of 
treatment differences might be conservative. 
Through week 15 of treatment, patients treated with nivolumab had stable EORTC QLQ-
C30 scale scores, whereas patients receiving IC had statistically significant and clinically 
meaningful worsening in physical, role, cognitive, and social functioning, as well as fatigue, 
dyspnea, insomnia, and appetite loss. There was no evidence of a differential benefit with 
nivolumab versus IC based on tumor PD-L1 expression status (<1% vs. ≥1%) or human 
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papillomavirus status (positive vs. negative). Nivolumab significantly delayed the time to 
deterioration versus IC for global health status; physical, role, cognitive, and social functioning; 
and symptoms of fatigue, dyspnea, insomnia, and appetite loss. 
With the EORTC QLQ-H&N35, patients treated with nivolumab also had stable scores 
through week 15 of treatment, whereas patients receiving IC had statistically significant and 
clinically meaningful worsening in sensory, social eating, social contact, and mouth-opening 
(trismus-related) problems, sticky saliva, feeling ill, painkiller use, and weight loss. In addition, 
nivolumab significantly delayed the time to deterioration versus IC for pain, sensory, social 
contact, and mouth-opening problems. There was no evidence of a differential benefit across 
tumor human papillomavirus status and PD-L1 expression subgroups. 
EQ-5D VAS scores showed that patients treated with nivolumab experienced clinically 
meaningful improvements from baseline to week 15, in contrast with clinically meaningful 
deteriorations in the IC arm. The difference between arms at week 15 was statistically 
significant (p = 0.037), clinically meaningful, and favored nivolumab. EQ-5D UI scores were 
similar for the two treatment arms with no statistically significant nor clinically meaningful 
differences observed within or between arms at weeks 9 and 15. 
An exploratory analysis found that some HRQoL measures correlated with healthcare 
resource utilization (HCRU; frequency of physician office visits, hospital outpatient visits, 
emergency department visits, hospital admissions, or other visits) (42). Higher baseline EORTC 
QLQ-C30 global health status (p = 0.040), cognitive functioning (p = 0.012), and social 
functioning (p = 0.011) were associated with lower total HCRU event frequency, while higher 
symptom burden was associated with more frequent total HCRU events. These correlations 
suggest that baseline HRQoL scores may be useful in identifying patients at risk of high HCRU. 
 
Discussion 
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PRO data reported across CheckMate clinical trials in melanoma, NSCLC, RCC, and 
SCCHN show that treatment with nivolumab stabilizes or improves HRQoL and symptom 
burden in patients with advanced cancer while providing clinical benefits, whereas comparators, 
both conventional chemotherapy and targeted agents, are more often associated with HRQoL 
deterioration. In addition, nivolumab delays time to symptom deterioration in multiple tumor 
types.   
The positive effect of nivolumab on PROs combines amelioration of disease-related 
symptoms and lower treatment toxicity reflecting nivolumab’s distinct mode of action, which 
does not involve direct cytotoxicity. Cytotoxicity of chemotherapy is not cancer-selective and 
results in AEs that can impact HRQoL. Although better tolerated, targeted agents are also 
associated with HRQoL-affecting AEs. Like nivolumab, ipilimumab’s mechanism of action relies 
on the generation of a T cell–mediated immune antitumor response. While immune-related AEs 
are very common in patients treated with immunotherapies, particularly an anti–CTLA-4 
antibody, the overall AE profiles of immuno-oncology agents are favorable compared with 
chemotherapy and targeted therapy (7). HRQoL, symptoms, and functioning assessed using 
PROs are an important part of the patient experience and may be a critical differentiating factor 
between PD-1 inhibitors and other treatments. 
In some instances, HRQoL advantages with nivolumab were observed prior to clinical 
benefits, potentially owing to currently undefined effects on circulating factors (e.g. 
cytokines/chemokines) that mediate symptoms and affect functioning. It is also possible that, in 
open-label trials, patients’ knowledge of received therapy affected their perception of the 
treatment and their HRQoL (43).  
 
Relevance and limitations of PRO assessments 
 Reporting the patient perspective is becoming particularly important in the development 
of therapies that may require longer duration of treatment. For some indications, PROs may 
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distinguish between available therapies when comparative clinical data are not available, 
enabling physicians and patients to make informed therapeutic decisions. PROs have 
prognostic capacity, which could be useful for tailoring therapeutic approaches to patient needs 
(39, 40, 42). Collection of PROs in routine clinical practice, while still infrequent, leads to more 
effective patient-centered care, improved patient-physician communication and patient 
satisfaction, and has been linked to extended survival (44-47). 
There is increasing demand to demonstrate value, particularly for novel therapeutic 
approaches that have high direct costs. Value frameworks encompassing benefits, toxicity, and 
cost of therapy are used to quantify the net value of cancer therapies, enabling comparisons, 
formulary prioritization, and cost-effectiveness assessments. Although the value framework 
designed by the Institute for Clinical and Economic Review uses quality-adjusted life years (48), 
and that of the European Society for Medical Oncology enables optional weighting of efficacy 
outcomes based on HRQoL (49), most do not yet require the inclusion of PROs in their metrics; 
this has been recognized as a limitation of the current models and will be addressed in future 
versions (50-52). It is expected that PROs will increasingly be included in health technology 
assessments, which will impact reimbursements, pricing negotiations, and market access (53).    
Stakeholders including regulatory bodies have started to commit to more patient-focused 
cancer drug development and the inclusion of PROs in oncology clinical trials (albeit not as 
primary endpoints) (54). The importance of PROs is reflected in the updated US Food and Drug 
Administration (FDA) and European Medicines Agency drug approval processes (1, 55). PRO 
findings are encouraged (but not required) to be included as part of the regulatory approval 
submission package, both in the United States and in Europe, and data collected rigorously 
using appropriate, reliable, and validated instruments can be included in product labels (54). 
Nevertheless, between 2010 and 2014, only three of the 40 newly approved anticancer drugs 
reviewed by the FDA had PRO-related labeling, demonstrating the challenges of integrating 
PRO assessments in clinical trials and in the oncology drug approval process (56). Guidelines 
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for reporting clinical trial data promote transparent and accurate reporting of PROs, in an effort 
to facilitate interpretation of these complex data and their limitations, which are further 
compounded by factors such as the unblinded nature of many oncology studies (57, 58). 
Based on experience with PROs as additional endpoints in nivolumab trials, 
questionnaire completion rates remain a major area for improvement in order to generate robust 
data and conduct accurate analyses. Missing PRO data are common in oncology clinical trials, 
impacting confidence intervals and statistical power. Analyses become particularly difficult in 
cases of imbalanced missing data between trial arms such that the patient groups are no longer 
comparable, and may reflect differing clinical benefits. To mitigate the impact of missing data, 
analyses for handling missing data should be preplanned and tailored to each trial design and 
assessment characteristics. Missing data should be explored to evaluate the reasons for 
dropout and, depending on the assessment, adjustment methods such as imputation 
procedures, PPMs, and selection models can be used (1, 43, 55, 59). The analytic plan for 
missing data should be fully reported, along with a detailed methodology of PRO collection and 
analysis, baseline PRO results, and other study limitations, per the Consolidated Standards of 
Reporting Trials (CONSORT) PRO extension, which provides guidance for authors of 
publications describing PRO data from clinical trials (57, 60, 61).  
PRO completion rates could be improved by increasing patient and physician awareness 
of the value of PROs in clinical trials, as these assessments are sometimes viewed as less 
important and less robust than clinical outcomes. While patients generally consider PRO 
questionnaires to be useful, few clinicians have experience conducting HRQoL assessments, 
citing limited resources, uncertainty about the measure to use, and a perceived lack of impact 
on patient care (62, 63). In addition, the inclusion of PRO assessments in clinical trials is time-
consuming and logistically difficult, often resulting in the deprioritization of PRO endpoints.  
Members of the clinical study team should be trained to ensure PROs are properly 
administered and collected; detailed instructions should include their purpose and significance 
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for the study (64). Participating patients should receive clear instructions, and the importance of 
honest, independent, and complete responses should be conveyed (64). The burden of PRO 
assessments could be reduced through electronic data collection instead of using paper 
questionnaires. Tablets, smartphones, or telephone-based interactive voice-response systems 
would improve data accuracy and completion rates (65). Additionally, PROs should be 
assessed beyond treatment discontinuation (e.g. in association with survival follow-up); this is 
particularly important for therapies that provide durable responses and long-term survival. 
A limitation of existing cancer-specific PRO measures is that these instruments were not 
designed to evaluate immune-based therapies and may not fully capture the benefits and 
tolerability of these therapies. New or updated cancer-specific measures covering the 
symptomatic AEs of immunotherapies are needed. Relevant items from the PRO version of the 
Common Terminology Criteria for Adverse Events (PRO-CTCAE) could be incorporated in 
immuno-oncology clinical trial endpoints, although the PRO-CTCAE may not be sufficiently 
comprehensive in its current form to encompass all immune-related AEs (66, 67). 
 
Conclusions 
HRQoL results from eight clinical trials in four cancer types demonstrate that nivolumab 
treatment generally results in stabilized or improved PROs compared with deteriorations 
observed with the trial comparators. Transparent, accurate, and complete reporting of the 
patient perspective using PROs is important in patient-focused cancer drug development and 
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PRO instruments used in nivolumab studies. 
Focus of 
measure 




EORTC QLQ-C30 (21) Global health and functioncal domains: 
 Global health status/HRQoL scale (2 items) 
 Physical functioning (5 items) 
 Role functioning (2 items) 
 Emotional functioning (4 items) 
 Cognitive functioning (2 items) 
 Social functioning (2 items) 
Ranges from 0 to 100 
Higher score = better HRQoL 
10b and/or domain-
specific MIDs (27, 
28) 
Symptom domains: 
 Pain (2 items) 
 Nausea and vomiting (2 items) 
 Fatigue (3 items) 
 Dyspnea 
 Insomnia 
 Appetite loss 
 Constipation 
 Diarrhea 
 Financial difficulties 
Ranges from 0 to 100 
Higher score = higher symptom 
burden  









 Sensory problems 
 Social contact problems 
 Swallowing  
 Social eating problems 
 Speech problems 
 Reduced sexuality 
Ranges from 0 to 100 





 Opening mouth 
 Dry mouth 
 Sticky saliva 
 Coughing 
 Feeling ill 
 Painkiller use 
 Nutritional supplements 
 Use of a feeding tube 
 Weight loss 
 Weight gain 
FKSI-15 (24)  Work 
 Enjoy life 
 Bothered by side effects 
Ranges from 0 (no symptoms) to 
36 (worst symptoms) 
2–3 
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 Worry condition will worsen 
 Appetite 
 Sleep 





 Weight loss 













Ranges from 0 to 100 on a VAS  





 Symptom distress 
 Interference with activity level  
3 items combined on a scale of 0 
to 300 
Higher score = better HRQoL 
30 










 Usual activities 
 Pain/discomfort 
 Anxiety/depression 
Patient responses converted to a 
vector and weighted using the UK 
preference-weighting algorithm 
(69) to provide an aggregate 
measure of a respondent’s health 
state value to society, on a scale 
from 0 (dead) to 1 (full health) 
0.08 
EQ-5D VAS 
Single VAS representing health state today 
Ranges from 0 (worst state 
imaginable) to 100 (best health 
state imaginable) 
7 
Abbreviations: ASBI, Average Symptom Burden Index; EORTC, European Organisation for Research and Treatment of Cancer; EORTC QLQ-C30, EORTC 
Quality of Life Questionnaire Core 30; EORTC QLQ-H&N35, EORTC 35-Question Head and Neck Cancer-Specific Module; EQ-5D, EuroQoL five dimensions; 
FKSI-DRS, Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms; HRQoL, health-related quality of life; LCSS, Lung 
Cancer Symptom Scale; MID, minimally important difference; UI, utility index; VAS, visual analog scale. 
a MID is defined within each instrument. 
b Clinically important difference, not necessarily MID. 
c Also commonly accepted as the clinically important difference. 
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Table 2 
Summary of clinical outcomes from nivolumab studies reporting PRO measures. 

















Phase III III II III III IIIb/IV III III 
Blinding Double-blind Double-blind Double-blind Open-label Open-label N/A Open-label Open-label 
Treatments Nivo vs. DTIC Nivo vs. nivo + ipi 
vs. ipi 
Nivo + ipi vs. ipi Nivo vs. docetaxel Nivo vs. docetaxel Nivo Nivo vs. 
everolimus 




Median OS NR (nivo), 10.8 
mo (DTIC) 
NR (nivo + ipi), 
37.6 mo (nivo), 
19.9 mo (ipi) 
Not reported 9.2 mo (nivo), 6.0 
mo (docetaxel) 
12.2 mo (nivo), 
9.4 mo 
(docetaxel) 
Not yet published 25.0 mo (nivo), 
19.6 mo 
(everolimus) 
7.5 mo (nivo), 5.1 
mo (IC) 
Median PFS 5.1 mo (nivo), 2.2 
mo (DTIC) 
11.5 mo (nivo + 
ipi), 6.9 mo (nivo), 
2.9 mo (ipi) 
BRAF WT: NR 
(nivo + ipi), 4.4 mo 
(ipi) 
BRAF mut: 8.5 mo 
(nivo + ipi), 2.7 mo 
(ipi) 
3.5 mo (nivo), 2.8 
mo (docetaxel) 
2.3 mo (nivo), 4.2 
mo (docetaxel) 
Not yet published 4.6 mo (nivo), 4.4 
mo (everolimus) 
2.0 mo (nivo), 2.3 
mo (IC) 
ORR 40.0% (nivo) 
13.9% (DTIC) 
57.6% (nivo + ipi), 
43.7% (nivo), 
19.0% (ipi) 
BRAF WT: 61% 
(nivo + ipi), 11% 
(ipi) 
20% (nivo), 9% 
(docetaxel) 
19% (nivo), 12% 
(docetaxel) 
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BRAF mut: 52% 






95.5% (nivo + ipi), 
82.1% (nivo), 
86.2% (ipi) 
91.5% (nivo + ipi),
93.5% (ipi) 
58% (nivo), 86% 
(docetaxel) 
69% (nivo), 88% 
(docetaxel) 








55.0% (nivo + ipi), 
16.3% (nivo), 
27.3% (ipi) 
54.2% (nivo + ipi), 
23.9% (ipi) 
7% (nivo), 55% 
(docetaxel) 
10% (nivo), 54% 
(docetaxel) 

































 At baseline 
 Q6W on 
treatment 
 At follow-up 
visits 1 and 2 
 At baseline 
 At weeks 1 and 
5 of every 6-
week cycle for 
the first 6 mo 
 Then Q6W up to 
week 79 
 At follow-up 
visits 1 and 2  
 At baseline 
 Q6W for the first 
6 mo of the 
study 
 At baseline 
 Q4W (nivo) and 
Q3W 
(docetaxel) for 
the first 6 mo of 
the study, then 
Q6W 
 At follow-up 
visits 1 and 2 
 At baseline 
 Q4W (nivo) and 
Q3W 
(docetaxel) for 
the first 6 mo of 
the study, then 
Q6W 
 At follow-up 
visits 1 and 2 
 At baseline 
 Q6W for the first 
year of the 
study, then Q4W 
for the duration 
of treatment 
 At follow-up 
visits 1 and 2 
(EQ-5D only) 
 At baseline 
 Q4W on 
treatment 
 At follow-up 
visits 1 and 2 
 At survival visits 
(EQ-5D only) 
 At baseline 
 At week 9 then 
Q6W on 
treatment 








Exploratory Exploratory Exploratory 




















Robert et al. N 
Engl J Med 2015 
(10) 
Larkin et al. N 
Engl J Med 2015 
(11) 
Wolchok et al. N 
Engl J Med 2017 
(13) 
Postow et al. N 
Engl J Med 2015 
(9) 
Brahmer et al. N 
Engl J Med 2015 
(14) 
Borghaei et al. N 
Engl J Med 2015 
(8) 
– Motzer et al. N 
Engl J Med 2015 
(12) 
Ferris et al. N 




Long et al. Ann 
Oncol 2016 (30) 
Schadendorf et al. 
Eur J Cancer 
2017 (31) 
Abernethy et al. J 
Clin Oncol 2015 
(32)  
Reck et al. J 
Thorac Oncol 
2017 (33) 
Gralla et al. J Clin 
Oncol 2016 (35); 
Reck et al. Ann 
Oncol 2016 (36) 
Schwartzberg et 
al. Eur J Cancer 
2015 (37); Spigel 
et al. J Thorac 
Oncol 2016 (38) 
Cella et al. Lancet 
Oncol. 2016 (39); 
Grimm Oncol Ther 
2017 (40) 
Harrington et al. 
Lancet Oncol 
2017 (41) 
Abbreviations: BRAF mut, BRAF V600 mutation-positive tumors; BRAF WT, BRAF wild-type tumors; DTIC, dacarbazine; EORTC, European Organisation for 
Research and Treatment of Cancer; EORTC QLQ-C30, EORTC Quality of Life Questionnaire Core 30; EORTC QLQ-H&N35, EORTC 35-Question Head and 
Neck Cancer-Specific Module; EQ-5D, EuroQoL five dimensions; FKSI-DRS, Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related 
Symptoms; IC, investigator’s choice of methotrexate, docetaxel, or cetuximab; ipi, ipilimumab; LCSS, Lung Cancer Symptom Scale; N/A, not applicable; nivo, 
nivolumab; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PRO, patient-reported outcome; Q3W, every 3 
weeks; Q4W, every 4 weeks; Q6W, every 6 weeks; RCC, renal cell carcinoma; SCCHN, squamous cell carcinoma of the head and neck; TRAEs, treatment-
related adverse events.   
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Table 3 
Summary of PRO score changes within and between arms. 
Tumor 
type 
Study Tx arm n Baseline 
completion rates 
(%) 
Change from baseline (within arm) Difference between arms 
Statistically significant Clinically meaningfula Statistically significant 
Melanoma 066 Nivo 210 EQ-5D: 70 
QLQ-C30: 70 
EQ-5D UI: ↑ wk 7–49 
EQ-5D VAS: ↑ wk 25, 31, 37 
QLQ-C30: none 
EQ-5D UI: ↑ wk 37, 61, 67 
EQ-5D VAS: ↑ wk 31, 37, 49, 55, 
61 
QLQ-C30: none 
EQ-5D UI: favoring nivo, wk 7 
EQ-5D VAS: none 
QLQ-C30: none 
DTIC 208 EQ-5D: 65 
QLQ-C30: 65 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: none 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: none 
067 Nivo 316 EQ-5D: 84.5 
QLQ-C30: 85.1 
EQ-5D UI: ↑ wk 13 onward 
EQ-5D VAS: none 
QLQ-C30: NS 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: none 
EQ-5D UI: NS 
EQ-5D VAS: ipi worse than nivo, 
wk 7–13, 19–23, ipi worse than 




314 EQ-5D: 87.2 
QLQ-C30: 87.3 
EQ-5D UI: ↓ wk 7, ↑ to baseline 
wk 13 
EQ-5D VAS: none 
QLQ-C30: ↓ wk 7 role functioning, 
fatigue, appetite loss 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: ↓ wk 7 role 
functioning, fatigue, appetite loss 
Ipi 315 EQ-5D: 81.9 
QLQ-C30: 82.2 
EQ-5D UI: ↓ wk 7, ↑ to baseline 
wk 19 
EQ-5D VAS: ↓ wk 5–23 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: none 
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QLQ-C30: NS 
069 Nivo + 
ipi 
95 EQ-5D: 64.2 
QLQ-C30: 65.3 
EQ-5D UI: ↓ wk 7 
EQ-5D VAS: none 
QLQ-C30: ↑ emotional 
functioning 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: none 
NS 
Ipi 47 EQ-5D: 76.7 
QLQ-C30: 78.7 
EQ-5D UI: ↓ wk 7 
EQ-5D VAS: none 
QLQ-C30: ↑ emotional 
functioning 
EQ-5D UI: none 
EQ-5D VAS: none 
QLQ-C30: none 
NSCLC 017 Nivo 135 EQ-5D: 81.5 
LCSS: 77.8 
EQ-5D UI: ↑ wk 20, 24, 42, 48, 
54, 66 
EQ-5D VAS: ↑ wk 12, 20, 24, 30, 
36, 48, 66 
LCSS ASBI: ↑ wk 16–54 
LCSS 3-II: ↑ wk 24, 42–54, 66 
EQ-5D UI: ↑ wk 42–66, 78 
EQ-5D VAS: ↑ wk 24–48, 60–72, 
84 
LCSS ASBI: ↑ wk 42–84 
LCSS 3-II: ↑ wk 42–84 
EQ-5D UI: favoring nivo, wk 48, 
54 
EQ-5D VAS: favoring nivo, wk 12, 
48 
LCSS ASBI: favoring nivo, wk 
30–42 
LCSS 3-II: favoring nivo, wk 30–
54 
Doc 137 EQ-5D: 76.6 
LCSS: 78.1 
EQ-5D UI: none  
EQ-5D VAS: none 
LCSS ASBI: none 
LCSS 3-II: ↓ wk 30–36 
EQ-5D UI: ↓ wk 36 
EQ-5D VAS: none 
LCSS ASBI: ↓ wk 36 
LCSS 3-II: ↓ wk 30–36 
057 Nivo 292 EQ-5D: 83.6 
LCSS: 82.2 
EQ-5D UI: ↓ wk 4 
EQ-5D VAS: ↓ wk 4, ↑ wk 16–36 
LCSS ASBI: ↓ wk 4, ↑ wk 16–54 
LCSS 3-II: ↓ wk 4, ↑ wk 16–36, 48 
EQ-5D UI: none 
EQ-5D VAS: ↑ wk 24, 36 
LCSS ASBI: none 
LCSS 3-II: none 
EQ-5D UI: none 
EQ-5D VAS: none 
LCSS ASBI: favoring nivo, wk 12, 
24, 30, 42 
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Doc 290 EQ-5D: 80.0 
LCSS: 76.6 
EQ-5D UI: none 
EQ-5D VAS: none 
LCSS ASBI: ↓ wk 9 
LCSS 3-II: none 
EQ-5D UI: none 
EQ-5D VAS: none 
LCSS ASBI: none 
LCSS 3-II: none 
LCSS 3-II: favoring nivo, wk 24, 
30 
153 Nivo 620b EQ-5D: NS 
LCSS: NS 
EQ-5D UI: ↑ wk 12–24 
EQ-5D VAS: ↑ wk 12–24 
LCSS ASBI: NS 
LCSS 3-II: NS 
EQ-5D UI: none 
EQ-5D VAS: ↑ wk 18–30 
LCSS ASBI: none 
LCSS 3-II: none 
NA 
RCC 025 Nivo 410 EQ-5D: 88.9 
FKSI-DRS: 88.9 
EQ-5D UI: ↑ wk 28–92, 100 
EQ-5D VAS: ↑ wk 8–116 
FKSI-DRS: ↑ wk 20–104 
EQ-5D UI: NS 
EQ-5D VAS: NS 
FKSI-DRS: NS 
EQ-5D UI: favoring nivo, wk 8–
12, 24–44, 52–68, 80 
EQ-5D VAS: favoring nivo, wk 4–
68, 76–80, 88–92 
FKSI-DRS: favoring nivo, wk 4–
76 
Ever 411 EQ-5D: 86.6 
FKSI-DRS:86.4 
EQ-5D UI: ↓ wk 4–8 
EQ-5D VAS: ↓ wk 4–16, 24, 32–
36, 56 
FKSI-DRS: ↓ wk 4–32, 60–64 
EQ-5D UI: NS 
EQ-5D VAS: NS 
FKSI-DRS: ↓ wk 4–84 
SCCHN 141 Nivo 240 EQ-5D: 79.6 
QLQ-C30: 79.6 
QLQ-H&N35: 80.4 
EQ-5D UI: NS 
EQ-5D VAS: NS 
QLQ-C30: NS 
QLQ-H&N35: NS 
EQ-5D UI: none 
EQ-5D VAS: ↑ wk 15 
QLQ-C30: none 
QLQ-H&N35: ↑ painkiller use, 
weight loss, wk 9; ↑ painkiller 
use, wk 15; ↓ weight gainc, wk 9–
15 
EQ-5D UI: none 
EQ-5D VAS: favoring nivo, wk 15 
QLQ-C30: favoring nivo, role, and 
social functioning, fatigue, 
dyspnea, diarrhea, appetite loss, 
wk 9; role, physical, cognitive, 
and social functioning, pain, 
fatigue, dyspnea, appetite loss, 
insomnia, wk 15 
IC 121 EQ-5D: 74.4 
QLQ-C30: 75.2 
EQ-5D UI: NS 
EQ-5D VAS: NS 
EQ-5D UI: none 
EQ-5D VAS: ↓ wk 15 
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QLQ-H&N35: 75.2 QLQ-C30: NS 
QLQ-H&N35: NS 
 
QLQ-C30: ↓ appetite loss, wk 9; ↓ 
physical, role, cognitive, social 
functioning, fatigue, dyspnea, 
insomnia, appetite loss, wk 15 
QLQ-H&N35: ↓ sticky saliva, 
nutritional supplement use, 
weight gainc, wk 9; ↓ sensory 
problems, social eating problems, 
social contact problems, mouth-
opening, sticky saliva, feeling ill, 
painkiller use, weight loss, wk 15 
QLQ-H&N35: favoring nivo, pain, 
sensory problems, nutritional 
supplement use, wk 9; favoring 
nivo, pain, sensory problems, 
social contact problems, mouth-
opening problems, sticky saliva, 
coughing, feeling ill, painkiller 
use, weight loss, wk 15 
Abbreviations: 3-II, 3-Item Index; ASBI, Average Symptom Burden Index; doc, docetaxel; DTIC, dacarbazine; EQ-5D, EuroQoL five dimensions; ever, everolimus; 
FKSI-DRS, Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms; IC, investigator’s choice of methotrexate, docetaxel, 
or cetuximab; ipi, ipilimumab; LCSS, Lung Cancer Symptom Scale; n, number of patients randomized; NA, not applicable; nivo, nivolumab; NS, not specified; 
NSCLC, non-small cell lung cancer; PRO, patient-reported outcome; QLQ-C30, EORTC Quality of Life Questionnaire Core 30; QLQ-H&N35, EORTC 35-Question 
Head and Neck Cancer-Specific Module; RCC, renal cell carcinoma; SCCHN, squamous cell carcinoma of the head and neck; Tx, treatment; UI, utility index; VAS, 
visual analog scale. 
↑ = improvement; ↓ = deterioration. 
a Clinically meaningful change was defined as a change equal to or exceeding the MID of the scale. 
b Number of patients included in PRO analysis (single-arm study). 
c Per scale design, a decrease in score for weight gain indicates that patients experienced an increase in weight, which, for this patient population that is often 
affected by difficulties eating and by weight loss, can be viewed as a positive effect. 
Italic text indicates adjusted completion rates calculated using the number of patients with non-missing PRO data at baseline and data from ≥1 post-baseline visit, 
divided by the number of patients in the study at each respective time point. 
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Figures 
Fig. 1. Mean (95% confidence interval) on-treatment scores on EQ-5D 3-level version from 
CheckMate 017 (33). (A) EQ-5D utility index; (B) EQ-5D visual analog scale (VAS). Only time 
points that had data available for five or more patients in either treatment group are shown. 
Dashed lines represent the mean scores reported for a general United States population (34) 
and for a lung cancer population (18).  
 
Reprinted with permission from Reck M, et al. J Thorac Oncol. 2018;13(2):194–204. Copyright 
© 2018 International Association for the Study of Lung Cancer, with permission from Elsevier 
(33). 
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Fig. 2. Mean change from baseline in health-related quality of life (HRQoL) scores on 
Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms 
(FKSI-DRS) from CheckMate 025 (39). Only time points where data were available for five or 
more patients are shown. Number at risk shows the number of randomized patients with 
baseline plus at least one post-baseline HRQoL assessment with non-missing patient-reported 
outcome data. Time 0 indicates baseline. Bars show standard error.  
 
Reprinted with permission from Cella D, et al. Lancet Oncol. 2016;17(7):994–1003. Copyright © 
2016 Elsevier (39). 
 
